MCID: SHR001
MIFTS: 53

Short Bowel Syndrome

Categories: Fetal diseases, Gastrointestinal diseases, Genetic diseases, Liver diseases, Metabolic diseases, Rare diseases

Aliases & Classifications for Short Bowel Syndrome

MalaCards integrated aliases for Short Bowel Syndrome:

Name: Short Bowel Syndrome 12 73 20 58 36 54 44 15 70
Acquired Short Bowel Syndrome 12
Short Gut Syndrome 12

Characteristics:

Orphanet epidemiological data:

58
short bowel syndrome
Prevalence: 1-9/100000 (Europe);

Classifications:

Orphanet: 58  
Rare gastroenterological diseases


External Ids:

Disease Ontology 12 DOID:10605
KEGG 36 H01469
MeSH 44 D012778
NCIt 50 C99059
SNOMED-CT 67 204768009
MESH via Orphanet 45 D012778
UMLS via Orphanet 71 C0036992
Orphanet 58 ORPHA104008
UMLS 70 C0036992

Summaries for Short Bowel Syndrome

GARD : 20 Short bowel syndrome is a disorder characterized by malabsorption of nutrients due to problems involving the small intestine. The small intestine is the tube-shaped organ between the stomach and large intestine, which includes the duodenum, jejunum, and ileum, where most food digestion and nutrient absorption take place. The causes of short bowel syndrome in adults include Crohn disease, mesenteric ischemia, radiation enteritis, or surgical removal of half or more of the small intestine to treat intestinal diseases or injuries. In children the main causes include necrotizing enterocolitis, intestinal atresias, and intestinal volvulus. Signs and symptoms may include diarrhea, cramping, bloating, heartburn, dehydration, malnutrition, weight loss, food sensitivities, weakness, and fatigue. Examples of treatment include diet and nutritional support, intestinal surgeries, and, in some cases, intestinal transplantation.

MalaCards based summary : Short Bowel Syndrome, also known as acquired short bowel syndrome, is related to congenital short bowel syndrome and intestinal pseudo-obstruction, and has symptoms including pain, postoperative and postoperative nausea and vomiting. An important gene associated with Short Bowel Syndrome is CLMP (CXADR Like Membrane Protein), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs carbamide peroxide and Ursodeoxycholic acid have been mentioned in the context of this disorder. Affiliated tissues include small intestine, liver and colon, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 An intestinal disease that is characterized by a reduced ability to absorb nutrients due to the physical loss or the loss of function of a portion of the small and/or large intestine.

KEGG : 36 Short bowel syndrome (SBS), also called short gut syndrome or simply short gut, is a malabsorption disorder. It typically occurs in people who lost at least half of their small intestine due to surgical resection for various disorders, including crohn's disease, volvulus, cancer, or significant damage (injury, trauma). In infants, necrotizing enterocolitis is the most common cause for surgical resection of the small intestines. Patients usually experience symptoms that include abdominal pain, diarrhea. The main treatment is nutritional support such as oral rehydration, parenteral nutrition, enteral nutrition, vitamin and mineral supplements, and special diet. Currently, a recombinant analog of human glucagon-like peptide-2 (GLP-2) teduglutide associated with the treatment for SBS has been reported to improve intestinal absorption.

Wikipedia : 73 Short bowel syndrome (SBS, or simply short gut) is a malabsorption disorder caused by a lack of... more...

Related Diseases for Short Bowel Syndrome

Diseases in the Short Bowel Syndrome family:

Congenital Short Bowel Syndrome Primary Short Bowel Syndrome
Secondary Short Bowel Syndrome

Diseases related to Short Bowel Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 389)
# Related Disease Score Top Affiliating Genes
1 congenital short bowel syndrome 33.0 FLNA CLMP
2 intestinal pseudo-obstruction 32.2 SST FLNA CLMP
3 volvulus of midgut 31.7 SST PYY GCG
4 cholelithiasis 30.7 SST LEP GAST CCK
5 intestinal obstruction 30.5 IL6 GHRL FLNA
6 glucagonoma 30.3 SST GAST
7 peptic ulcer disease 30.2 SST GHRL GAST
8 ileus 30.2 SST IL6 GHRL CCK
9 gastrointestinal system disease 30.1 GHRL GCG GAST CCK
10 meckel diverticulum 30.1 SST GCG
11 bone disease 30.0 IL6 IGF1 HGF FLNA
12 esophagitis 29.9 NTS IL6 GAST
13 carcinoid syndrome 29.8 SST PYY NTS IGF1
14 hypoglycemia 29.8 SST IGF1 GH1 GCG
15 gallbladder disease 29.8 SST PYY CCK
16 insulin-like growth factor i 29.8 SST LEP IGF1 GH1 EGF
17 diarrhea 29.7 TTR SST PYY NTS LEP IL6
18 pancreatitis 29.7 SST IL6 GCG CCK
19 bone resorption disease 29.6 LEP IL6 IGF1
20 mucositis 29.2 HGF GLP2R GHRL FGF7 EGF
21 dumping syndrome 29.1 SST PYY NTS GHRL GCG GAST
22 protein-energy malnutrition 29.0 TTR LEP IL6 IGF1
23 hyperinsulinism 29.0 SST LEP IGF1 GHRL GH1 GCG
24 hypothyroidism 28.9 TTR SST LEP IGF1 GH1
25 arteriosclerosis 28.8 TTR IL6 HGF GHRL
26 celiac disease 1 28.6 PYY IL6 IGF1 GHRL GCG GAST
27 leptin deficiency or dysfunction 28.6 PYY LEP IL6 IGF1 GHRL GCG
28 constipation 28.6 SST PYY NTS IL6 GHRL GCG
29 osteoporosis 28.5 LEP IL6 IGF1 GHRL GH1 EGF
30 inflammatory bowel disease 28.4 SLC15A1 PYY NTS LEP IL6 IGF1
31 deficiency anemia 28.2 TTR IL6 IGF1 GHRL GH1
32 nutritional deficiency disease 27.7 TTR LEP IL6 IGF1 GHRL GH1
33 type 2 diabetes mellitus 26.8 TTR SST PYY NTS LEP IL6
34 diabetes mellitus 26.7 TTR SST PYY LEP IL6 IGF1
35 intestinal pseudoobstruction, neuronal, chronic idiopathic, x-linked 11.6
36 gastroschisis 11.2
37 abdominal wall defect 11.2
38 primary short bowel syndrome 11.1
39 secondary short bowel syndrome 11.1
40 enterocolitis 10.8
41 perinatal necrotizing enterocolitis 10.7
42 overgrowth syndrome 10.7
43 liver disease 10.7
44 cholestasis 10.7
45 lactic acidosis 10.6
46 intestinal atresia 10.6
47 crohn's disease 10.6
48 metabolic acidosis 10.4
49 gastrointestinal neuroendocrine benign tumor 10.4 SST GAST
50 non-functioning pancreatic endocrine tumor 10.4 SST GAST

Graphical network of the top 20 diseases related to Short Bowel Syndrome:



Diseases related to Short Bowel Syndrome

Symptoms & Phenotypes for Short Bowel Syndrome

UMLS symptoms related to Short Bowel Syndrome:


pain, postoperative; postoperative nausea and vomiting

GenomeRNAi Phenotypes related to Short Bowel Syndrome according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 9.64 FLNA
2 Decreased viability GR00055-A-2 9.64 FLNA
3 Decreased viability GR00221-A-1 9.64 HGF
4 Decreased viability GR00221-A-2 9.64 HGF
5 Decreased viability GR00221-A-4 9.64 HGF
6 Decreased viability GR00240-S-1 9.64 SST
7 Decreased viability GR00249-S 9.64 AOC1 FGF7 FLNA GCG GH1 GHRL
8 Decreased viability GR00381-A-1 9.64 PYY
9 Decreased viability GR00386-A-1 9.64 CCK CLMP FGF7 FLNA GCG TTR
10 Decreased viability GR00402-S-2 9.64 PYY

MGI Mouse Phenotypes related to Short Bowel Syndrome:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.97 AOC1 CCK CLMP FGF7 FLNA GHRL
2 adipose tissue MP:0005375 9.86 GHRL GLP2R IGF1 IL6 LEP NTS
3 digestive/alimentary MP:0005381 9.7 CLMP EGF FLNA GAST GHRL GLP2R
4 homeostasis/metabolism MP:0005376 9.5 AOC1 CCK CLMP FGF7 FLNA GAST

Drugs & Therapeutics for Short Bowel Syndrome

Drugs for Short Bowel Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 60)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
carbamide peroxide Approved Phase 4 124-43-6
2
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
3
Apixaban Approved Phase 4 503612-47-3 10182969
4
Aspartic acid Approved, Nutraceutical Phase 4 56-84-8 5960
5 N-Methylaspartate Phase 4
6
Bilirubin Phase 4 635-65-4 5280352
7 Plasminogen Phase 4
8 Tissue Plasminogen Activator Phase 4
9 Serine Proteinase Inhibitors Phase 4
10 Anticoagulants Phase 4
11 Factor Xa Inhibitors Phase 4
12 Antithrombin III Phase 4
13 Antithrombins Phase 4
14
protease inhibitors Phase 4
15 HIV Protease Inhibitors Phase 4
16 glutamine Phase 4
17 Dipeptidyl-Peptidase IV Inhibitors Phase 4
18 Sitagliptin Phosphate Phase 4
19
L-Alanine Nutraceutical Phase 4 56-41-7 5950
20
Serine Investigational, Nutraceutical Phase 4 56-45-1 5951
21
Teduglutide Approved Phase 3 197922-42-2
22 Omega 3 Fatty Acid Phase 2, Phase 3
23 Fat Emulsions, Intravenous Phase 2, Phase 3
24 Protective Agents Phase 3
25 Radiation-Protective Agents Phase 3
26 Gastrointestinal Agents Phase 3
27
Pancrelipase Approved, Investigational Phase 2 53608-75-6
28 Soybean oil, phospholipid emulsion Phase 2
29 Parenteral Nutrition Solutions Phase 2
30 Nutrients Phase 2
31 Mitogens Phase 2
32 pancreatin Phase 2
33 Cholestyramine Resin Phase 2
34 Lipid Regulating Agents Phase 2
35 Anticholesteremic Agents Phase 2
36 Antimetabolites Phase 2
37 Hypolipidemic Agents Phase 2
38 Immunologic Factors Phase 1
39 Vaccines Phase 1
40
Vitamin D Approved, Nutraceutical, Vet_approved 1406-16-2
41
Ergocalciferol Approved, Nutraceutical 50-14-6 5280793
42
Vitamin D3 Approved, Nutraceutical 67-97-0 5280795 6221
43 Cola
44 Tin Fluorides
45 Trace Elements
46 Calciferol
47 Micronutrients
48 Acidophilus
49 Antibiotics, Antitubercular
50 Anti-Bacterial Agents

Interventional clinical trials:

(show top 50) (show all 106)
# Name Status NCT ID Phase Drugs
1 Influence of Recombinant Human Growth Hormone on Intestinal Permeability and Liver Injury in Intestinal Failure Patients Receiving Parenteral Nutrition (Serono Project) Completed NCT01380366 Phase 4 Somatropin
2 A Monocentric Single-arm Study to Characterize the Long-term Safety, Efficacy, and Pharmacodynamic of GLP-2 Analog (Revestive®) in the Management of Short Bowel Syndrome Pediatric Patients on Home-parenteral Nutrition (HPN) Completed NCT03562130 Phase 4 Teduglutide
3 Prophylactic Recombinant Tissue Plasminogen Activator in the Prevention of Central Venous Access Device (CVAD)-Associated Thrombosis and Infection in Pediatric Patients With Short Bowel Syndrome Completed NCT02355743 Phase 4 rtPA lock therapy
4 The Preventative and Therapeutical Effect of Ursodeoxycholic Acid(UDCA) to Parenteral Nutrition-associated Cholestasis in Short Bowel Syndrome Completed NCT01974336 Phase 4 ursodeoxycholic acid
5 Acute Effects of a Glucagon-like Peptide 2 Analog, Teduglutide, on Gastrointestinal Motor Function and Permeability in Patients With Short Bowel Syndrome on Home Parenteral Nutrition Completed NCT02099084 Phase 4 Teduglutide;Placebo
6 Pharmacokinetics of Apixaban in Patients With Short Bowel Syndrome Requiring Long Term Parenteral Nutrition Not yet recruiting NCT04344717 Phase 4 Apixaban single dose
7 An Open-label Evaluation of the Long-term Efficacy and Safety of a Standardized Regimen of Growth Hormone, Glutamine and a Modified Diet in the Treatment of Patients With Short Bowel Syndrome Terminated NCT00742157 Phase 4 Growth Hormone
8 The Use of Dipeptidyl Peptidase-4 Inhibitor Influences the Absorption of Intestine in Short Bowel Syndrome Terminated NCT02653131 Phase 4 Dipeptidyl peptidase-4 inhibitor
9 Acute Effects of a Glucagon-like Peptide 1 Analog, Exenatide, on Gastrointestinal Motor Function and Permeability in Patients With Short Bowel Syndrome on Home Parenteral Nutrition Withdrawn NCT01818648 Phase 4 Exenatide;Placebo
10 Safety and Efficacy of SMOFlipid in Patients Intolerant to Intralipid. Withdrawn NCT03054948 Phase 4 SMOFLipid;Standard therapy
11 A 24-Week Double-blind, Safety, Efficacy, and Pharmacodynamic Study Investigating Two Doses of Teduglutide in Pediatric Subjects Through 17 Years of Age With Short Bowel Syndrome Who Are Dependent on Parenteral Support Completed NCT02682381 Phase 3 Teduglutide 0.05mg/kg;Teduglutide 0.025 mg/kg
12 Use of Omegaven for Parenteral Nutrition Associated Liver Disease Completed NCT01194063 Phase 3 Omega-3 fish oil lipid emulsion
13 A 24-Week Study of the Efficacy and Safety of Teduglutide in Subjects With Parenteral Nutrition-Dependent Short Bowel Syndrome Completed NCT00798967 Phase 3 teduglutide;placebo
14 A Long-Term, Open-Label Study With Teduglutide for Subjects With Parenteral Nutrition Dependent Short Bowel Syndrome Completed NCT00930644 Phase 3 teduglutide
15 A Prospective, Open-label, Long-term Safety and Efficacy Study of Teduglutide in Pediatric Patients With Short Bowel Syndrome Who Completed TED-C14-006 or SHP633-301 Completed NCT02954458 Phase 3 TED
16 Evaluation of the Efficacy and Safety of Recombinant Human Growth Hormone (rhGH) in the Treatment of Children With Short Bowel Syndrome Completed NCT00169637 Phase 3 rhGH
17 A 24-week Safety, Efficacy, Pharmacodynamic, and Pharmacokinetic Study of Teduglutide in Japanese Pediatric Subjects, Aged 4 Months Through 15 Years, With Short Bowel Syndrome Who Are Dependent on Parenteral Support Completed NCT02980666 Phase 3 Teduglutide
18 A Study of the Safety and Efficacy of Teduglutide in Subjects With Parenteral Nutrition-Dependent Short Bowel Syndrome Who Completed Protocol CL0600-004 (NCT00081458) Completed NCT00172185 Phase 3 teduglutide 0.05 mg/kg/d;teduglutide 0.10 mg/kg/d
19 A Study of the Efficacy and Safety of Teduglutide in Subjects With Parenteral Nutrition-Dependent Short Bowel Syndrome Completed NCT00081458 Phase 3 Placebo;Teduglutide 0.05 mg/kg/d;Teduglutide 0.1 mg/kg/d
20 A 24-Week Safety, Efficacy, Pharmacokinetic Study of Teduglutide in Japanese Subjects With Short Bowel Syndrome Who Are Dependent on Parenteral Support Completed NCT03663582 Phase 3 Teduglutide
21 A Randomized, Open-label, 24-Week Safety, Efficacy, and Pharmacokinetic Study of Teduglutide in Infants 4 to 12 Months of Age With Short Bowel Syndrome Who Are Dependent on Parenteral Support Completed NCT03571516 Phase 3 Teduglutide
22 A 4-Stage, Open-label, Multicenter Study Including Long-term Extension to Evaluate the Safety, Efficacy and Pharmacokinetics of Teduglutide in Japanese Subjects With PN-dependent Short Bowel Syndrome Completed NCT02340819 Phase 3 Teduglutide
23 A Retrospective and Prospective, Open-label, Long-term Safety and Efficacy Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome Who Completed TED-C13-003 Completed NCT02949362 Phase 3 Teduglutide
24 A One-Year, Open-Label Study With Teduglutide for Subjects With Parenteral Nutrition-dependent Short Bowel Syndrome Who Completed Study CL0600-021 Completed NCT01560403 Phase 3 Teduglutide
25 A 12-Week Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects Aged 1 Year Through 17 Years, With Short Bowel Syndrome Who Are Dependent on Parenteral Support Completed NCT01952080 Phase 3 teduglutide
26 Fish Oil Lipid Emulsion for the Treatment of Parenteral-Nutrition-Associated Liver Disease in Infants Completed NCT02370251 Phase 2, Phase 3 Omegaven
27 Cholestasis Reversal: Efficacy of IV Fish Oil Completed NCT00910104 Phase 2, Phase 3 Omegaven®
28 A Double-Blind Phase 3 Extension Trial Assessing the Long Term Safety and Efficacy of Glepaglutide in Patients With Short Bowel Syndrome (SBS) Recruiting NCT03905707 Phase 3 glepaglutide
29 A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Glepaglutide in Patients With Short Bowel Syndrome (SBS) Recruiting NCT03690206 Phase 3 glepaglutide;Placebo
30 A Multicenter, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Apraglutide in Adult Subjects With Short Bowel Syndrome and Intestinal Failure (SBS-IF) Recruiting NCT04627025 Phase 3 apraglutide
31 An Open-Label, Extension Study of Teduglutide in Japanese Subjects With Short Bowel Syndrome Who Completed 24 Weeks of Treatment in SHP633-306 or TED-C14-004 Active, not recruiting NCT03596164 Phase 3 Teduglutide
32 A Prospective, Open-label, Long-term Safety and Efficacy Study of Teduglutide in Japanese Pediatric Subjects With Short Bowel Syndrome Who Completed SHP633-302 Active, not recruiting NCT03268811 Phase 3 Teduglutide
33 Pilot Study to Investigate the Effect of Teduglutide on Temporary Ileostomy Function and Complications Not yet recruiting NCT03953170 Phase 3 Teduglutide;Placebo
34 A Multi-Center, Randomized, Double-Blind, Three-Arm, Parallel-Group Trial to Assess the Efficacy and Safety of NTRA-9620 in Infants With Short Bowel Syndrome (SBS) Following Surgical Resection Terminated NCT02865122 Phase 2, Phase 3 NTRA-9620;Placebo
35 Loperamide vs. Placebo's Effect on Ileostomy Output: A Clinical Randomized Blinded Cross-over Study Terminated NCT02266849 Phase 3 Loperamide;Placebo
36 A Phase 3, Open Label Responder Treatment Period With a Randomized, Blinded, Three-Period Crossover, Followed by an Open Label Safety Period to Evaluate the Clinical Efficacy, Safety, and Pharmacokinetics of Investigational Drug MP-101 (Opium Tincture and Opium Tincture With Reduced Uncharacterized Material) to Treat Chronic Diarrhea in Subjects With Short Bowel Syndrome Who Have Had an Inadequate Response to Anti-Diarrheals Withdrawn NCT02242656 Phase 3 Opium Tincture USP Deodorized;Opium Tincture USP Deodorized
37 A Phase 3, Open Label Extension Study for Subjects That Complete Study MP-101-CL-001 Withdrawn NCT02246816 Phase 3 0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized)
38 Efficacy and Safety of Omega-3 Lipid Therapy in Pediatric Patients With Parenteral Nutrition-Associated Liver Disease Unknown status NCT01739517 Phase 2 Omegaven Therapy
39 Can SMOFlipid®, A Composite Parenteral Nutrition Lipid Emulsion, Prevent Progression Of Parenteral Nutrition Associated Liver Disease In Infants? A Pilot Double Blind Randomized Controlled Trial Unknown status NCT00793195 Phase 2 Intralipid 20%;SMOFlipid 20%
40 Diet/Growth Factor Mechanisms of Gut Adaptation Completed NCT00067860 Phase 2 recombinant human growth hormone
41 Use of Pancreatic Enzymes in Short Bowel Syndrome Completed NCT03097029 Phase 2 Pancreatic Enzyme
42 A Phase 2 Trial Testing ZP1848 in Patients With SBS Completed NCT02690025 Phase 2 ZP1848
43 A Phase Ib/IIa Open-label, Repeated Dose, Metabolic Balance Study of FE 203799 in Patients With Short Bowel Syndrome and Intestinal Insufficiency Completed NCT03408132 Phase 1, Phase 2 FE203799
44 A Once-weekly, Repeated Dose, Placebo Controlled, Double Blind, Randomised Cross-over Trial Investigating Safety, Efficacy and Pharmacodynamics of FE 203799 in Patients With Short Bowel Syndrome With Intestinal Failure Requiring Parenteral Support Followed by an Additional Treatment Period in an Open Label Regimen. Completed NCT03415594 Phase 1, Phase 2 FE203799 GLP-2 analogue;FE203799 Placebo GLP-2 analogue;FE203799 GLP-2 analogue
45 Early Supplementation of Enteral Microlipid With and Without Fish Oil in Premature Infants With Enterostomies Completed NCT01674478 Phase 2
46 A Phase IIa, Proof of Concept, Randomized, Double-Blind, Dose-Finding, Cross-Over Study of the Efficacy, Safety and Tolerability of a New Enteric-Coated Cholestyramine Capsule in Adult Short Bowel Syndrome Patients Recruiting NCT04046328 Phase 2 Enteric-Coated Cholestyramine (ECC) Capsule;Placebo
47 A Phase I/II Proof of Concept, Open-Label, Repeat Dose, Dose Escalation Study of NM-002 in Adult Patients With Short Bowel Syndrome (SBS) Active, not recruiting NCT04379856 Phase 1, Phase 2 NM-002
48 Functional Sucrase Deficiency in Short Bowel Syndrome Patients With Intestinal Failure Not yet recruiting NCT04604275 Phase 2 Sucrase
49 A Multicenter, Proof-of-concept, Phase 2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HM15912 in Adult Subjects With Short Bowel Syndrome-associated Intestinal Failure (SBS-IF) Not yet recruiting NCT04775706 Phase 2 HM15912 Active;Placebo
50 Phase 1-2 Trial of Glucagon-like Peptide 2 (GLP-2) in Infants and Children With Intestinal Failure Terminated NCT01573286 Phase 1, Phase 2 Glucagon-Like Peptide 2;Glucagon like peptide-2

Search NIH Clinical Center for Short Bowel Syndrome

Cochrane evidence based reviews: short bowel syndrome

Genetic Tests for Short Bowel Syndrome

Anatomical Context for Short Bowel Syndrome

MalaCards organs/tissues related to Short Bowel Syndrome:

40
Small Intestine, Liver, Colon, Kidney, Bone, Smooth Muscle, Skin

Publications for Short Bowel Syndrome

Articles related to Short Bowel Syndrome:

(show top 50) (show all 3559)
# Title Authors PMID Year
1
The use of GLP-2 and related growth factors in intestinal diseases. 54 61
20336592 2010
2
Medical management of pediatric intestinal failure. 61 54
20123270 2010
3
Population pharmacokinetics of teduglutide following repeated subcutaneous administrations in healthy participants and in patients with short bowel syndrome and Crohn's disease. 61 54
19773525 2010
4
Colonic GLP-2 is not sufficient to promote jejunal adaptation in a PN-dependent rat model of human short bowel syndrome. 54 61
19644131 2009
5
Short bowel syndrome: the role of GLP-2 on improving outcome. 54 61
19474717 2009
6
Ghrelin does not predict adaptive hyperphagia in patients with short bowel syndrome. 61 54
19176401 2009
7
Growth factor based therapies and intestinal disease: is glucagon-like peptide-2 the new way forward? 54 61
19324585 2009
8
Short bowel patients treated for two years with glucagon-like peptide 2 (GLP-2): compliance, safety, and effects on quality of life. 61 54
19590736 2009
9
Short bowel patients treated for two years with glucagon-like Peptide 2: effects on intestinal morphology and absorption, renal function, bone and body composition, and muscle function. 54 61
19707516 2009
10
GLP-2 administration results in increased proliferation but paradoxically an adverse outcome in a juvenile piglet model of short bowel syndrome. 54 61
18162829 2008
11
Review article: glucagon-like peptide 2--current applications and future directions. 54 61
17217448 2007
12
Gut hormones, and short bowel syndrome: the enigmatic role of glucagon-like peptide-2 in the regulation of intestinal adaptation. 61 54
16830359 2006
13
Teduglutide for the treatment of short bowel syndrome. 61 54
16705029 2006
14
Glucagon-like peptide-2: update of the recent clinical trials. 61 54
16473060 2006
15
Dipeptidyl-peptidase IV in patients with short bowel syndrome. 61 54
16169633 2005
16
Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. 61 54
16099790 2005
17
Intestinal growth in parenterally-fed rats induced by the combined effects of glucagon-like peptide 2 and epidermal growth factor. 61 54
15961680 2005
18
A pilot study of the use of epidermal growth factor in pediatric short bowel syndrome. 61 54
15937810 2005
19
Nutrient-stimulated GLP-2 release and crypt cell proliferation in experimental short bowel syndrome. 61 54
15388486 2005
20
Growth factors and trefoil peptides in gastrointestinal health and disease. 54 61
15525545 2004
21
Comparative effects of glucagon-like peptide-2 (GLP-2), growth hormone (GH), and keratinocyte growth factor (KGF) on markers of gut adaptation after massive small bowel resection in rats. 61 54
15568286 2004
22
Glucagon-like peptide 2 (GLP-2), an intestinotrophic mediator. 61 54
14965320 2004
23
[Glucagon-like peptides--synthesis, biological actions and some clinical implications]. 54 61
15803906 2004
24
Dual regulation of cell proliferation and survival via activation of glucagon-like peptide-2 receptor signaling. 61 54
14608100 2003
25
Epidermal growth factor improves nutritional outcome in a rat model of short bowel syndrome. 54 61
11987096 2002
26
Gut adaptation and the glucagon-like peptides. 54 61
11839727 2002
27
Biological actions and therapeutic potential of the glucagon-like peptides. 61 54
11832466 2002
28
Enhancement of intestinal growth and repair by growth factors. 61 54
11757811 2001
29
Glucagon-like peptide 2. 61 54
11297614 2001
30
Cholecystokinin (CCK) secretion in patients with severe short bowel syndrome (SSBS). 61 54
11330425 2001
31
Keratinocyte growth factor enhances early gut adaptation in a rat model of short bowel syndrome. 54 61
10653491 2000
32
Epidermal growth factor and the short bowel syndrome. 61 54
10483910 1999
33
Enterotrophic effects of glucagon-like peptide 2 are enhanced by neurotensin. 61 54
10482697 1999
34
Clinical use of growth hormone and glutamine in short bowel syndrome. 54 61
10488599 1999
35
Epidermal growth factor stimulates the recovery of glucose absorption after small bowel transplantation. 54 61
9878331 1998
36
Enteral glutamine does not enhance the effects of hepatocyte growth factor in short bowel syndrome. 54 61
9856891 1998
37
Epidermal growth factor selectively enhances functional enterocyte adaptation after massive small bowel resection. 54 61
9070188 1997
38
Octreotide diminishes luminal nutrient transport activity, which is reversed by epidermal growth factor. 61 54
8862081 1996
39
Epidermal growth factor improves intestinal adaptation during somatostatin administration in vivo. 54 61
8661191 1996
40
Potential indications for octreotide in gastroenterology: summary of workshop. 61 54
8359570 1993
41
Somatostatin and its analogs in the short bowel syndrome. 61 54
1363486 1992
42
Aminoguanidine blocks intestinal diamine oxidase (DAO) activity and enhances the intestinal adaptive response to resection in the rat. 54 61
2124566 1990
43
Long-term outcomes of various pediatric short bowel syndrome in China. 61
33394086 2021
44
Positioning strictureplasty in the treatment of extensive Crohn's disease ileitis: a comparative study with ileocecal resection. 61
33479821 2021
45
Prevalence of home parenteral nutrition in children. 61
33745567 2021
46
Aggressive nutrition therapy in malnutrition and sarcopenia. 61
33453622 2021
47
Twelve year outcomes of intestinal failure associated liver disease in children with short bowel syndrome: 97% transplant-free survival and 81% enteral autonomy. 61
33794031 2021
48
Teduglutide for pediatric short bowel syndrome patients. 61
33798402 2021
49
Technical innovations for autologous intestinal reconstruction surgery in children with short bowel syndrome. 61
33403476 2021
50
An organoid-based organ-repurposing approach to treat short bowel syndrome. 61
33627870 2021

Variations for Short Bowel Syndrome

Expression for Short Bowel Syndrome

Search GEO for disease gene expression data for Short Bowel Syndrome.

Pathways for Short Bowel Syndrome

Pathways related to Short Bowel Syndrome according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.55 TTR SST PYY NTS LEP IL6
2
Show member pathways
13.46 SST PYY NTS LEP GLP2R GHRL
3
Show member pathways
13.18 IL6 IGF1 HGF GH1 FLNA FGF7
4
Show member pathways
12.96 IL6 IGF1 HGF GH1 FGF7 EGF
5
Show member pathways
12.94 IL6 IGF1 HGF GH1 FGF7 EGF
6
Show member pathways
12.86 IL6 IGF1 HGF GH1 FGF7 EGF
7 12.73 IL6 IGF1 HGF FGF7 EGF
8 12.66 IGF1 HGF FLNA FGF7 EGF
9
Show member pathways
12.5 IL6 IGF1 HGF GH1 FGF7 EGF
10
Show member pathways
12.3 LEP IL6 GH1 EGF
11
Show member pathways
12.25 IL6 IGF1 HGF GH1 FGF7 EGF
12
Show member pathways
12.14 IL6 IGF1 HGF GH1 FGF7
13
Show member pathways
12.03 LEP IGF1 GHRL GH1 GCG
14 11.93 LEP IL6 IGF1 GH1
15 11.74 LEP IL6 IGF1 EGF
16 11.68 IL6 IGF1 HGF FGF7 EGF
17 11.49 IL6 IGF1 HGF GH1 FGF7 EGF
18 11.24 IL6 IGF1 HGF EGF
19 10.91 PYY LEP GHRL
20 10.87 IL6 IGF1 HGF GH1 FGF7 EGF
21 10.82 IL6 IGF1 HGF FGF7 EGF
22 10.4 GAST CCK

GO Terms for Short Bowel Syndrome

Cellular components related to Short Bowel Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.83 TTR SST PYY LEP IL6 IGF1
2 extracellular region GO:0005576 9.55 TTR SST PYY NTS LEP IL6
3 platelet alpha granule lumen GO:0031093 9.33 IGF1 HGF EGF

Biological processes related to Short Bowel Syndrome according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 10.01 SST PYY NTS GLP2R GHRL GCG
2 signal transduction GO:0007165 9.9 TTR NTS LEP IL6 IGF1 GLP2R
3 positive regulation of cell proliferation GO:0008284 9.87 LEP IL6 IGF1 GLP2R FGF7 EGF
4 positive regulation of protein kinase B signaling GO:0051897 9.85 LEP HGF FGF7 EGF
5 regulation of cell migration GO:0030334 9.8 SST FLNA FGF7
6 activation of MAPK activity GO:0000187 9.8 IGF1 HGF GHRL EGF
7 negative regulation of apoptotic process GO:0043066 9.8 LEP IL6 IGF1 HGF GHRL GCG
8 response to nutrient levels GO:0031667 9.78 LEP GHRL GH1
9 regulation of insulin secretion GO:0050796 9.76 LEP IL6 GCG
10 platelet degranulation GO:0002576 9.76 IGF1 HGF FLNA EGF
11 positive regulation of osteoblast differentiation GO:0045669 9.74 IL6 IGF1 HGF
12 positive regulation of MAPK cascade GO:0043410 9.73 LEP IL6 IGF1 EGF
13 response to activity GO:0014823 9.71 LEP IL6 GCG
14 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.67 LEP IL6 IGF1 GH1
15 positive regulation of JAK-STAT cascade GO:0046427 9.65 LEP IL6 GH1
16 positive regulation of growth GO:0045927 9.62 GHRL GH1
17 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.61 IGF1 GH1
18 negative regulation of appetite GO:0032099 9.6 LEP CCK
19 adult feeding behavior GO:0008343 9.59 LEP GHRL
20 negative regulation of lipid storage GO:0010888 9.58 LEP IL6
21 bone mineralization involved in bone maturation GO:0035630 9.56 LEP IGF1
22 myoblast proliferation GO:0051450 9.52 IGF1 HGF
23 regulation of branching involved in salivary gland morphogenesis by mesenchymal-epithelial signaling GO:0060665 9.51 HGF FGF7
24 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.35 LEP IGF1 HGF GH1 EGF
25 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.17 IL6 IGF1 HGF GH1 FGF7 EGF

Molecular functions related to Short Bowel Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor binding GO:0001664 9.43 PYY GHRL FLNA
2 growth factor activity GO:0008083 9.43 IL6 IGF1 HGF GH1 FGF7 EGF
3 neuropeptide hormone activity GO:0005184 9.33 PYY NTS CCK
4 peptide hormone receptor binding GO:0051428 9.32 LEP CCK
5 hormone activity GO:0005179 9.32 TTR SST PYY LEP IGF1 GHRL

Sources for Short Bowel Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....